Vitamin E antioxidants to slow the progression of Alzheimer's Disease. M. Sano et al. New Eng J Med, Vol 336, pp. 1216-22, 1997
Vitamin E antioxidants to slow the progression of Alzheimer’s Disease. M. Sano et al. New Eng J Med, Vol 336, pp. 1216-22, 1997
In a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer’s disease of moderate severity, a total of 341 patients received the MAOI drug selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and vitamin E, or placebo for two years. The researchers monitored for time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). The average time to these outcomes for each group were selegiline 655 days, vitamin E 670 days, combination 585 days, and placebo 440 days. The researchers concluded that in patients with moderately severe impairment from Alzheimer’s disease, treatment with selegiline or vitamin E slows the progression of disease.
M Sano et al., ‘A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study’, N Engl J Med. Apr 24;336(17):1216-22, 1997
Click here for the abstract